. 2019 Mar 13;175(3):701–712. doi: 10.1007/s10549-019-05197-w

Table 3.

QoL and symptom severity at start of treatment (T0)

Scale	Range	Premenopausal (n = 251)		Postmenopausal (n = 478)
Scale	Range	n	Mean ± SD	n	Mean ± SD
FACT-G^a
FACT-G global score	0–108	233	75.5 ± 15.40	426	75.8 ± 15.89
Physical well-being	0–28	236	18.4 ± 6.28	436	18.9 ± 6.40
Social/family well-being	0–28	235	23.1 ± 4.68	429	22.9 ± 4.81
Emotional well-being	0–24	237	17.9 ± 4.09	436	17.9 ± 4.45
Functional well-being	0–28	237	15.9 ± 5.89	436	15.9 ± 5.87
FACT-Taxane^a
FACT-Taxane subscale	0–64	231	58.7 ± 5.59	434	57.0 ± 7.82
FACT-ES^a
Endocrine Symptom Subscale-18	0–72	235	59.8 ± 7.45	436	60.2 ± 8.15
EORTC QLQ-BR23^a
Body image	0–100	235	64.3 ± 30.40	436	70.0 ± 30.05
Future perspective	0–100	232	47.0 ± 31.33	434	44.5 ± 31.75
Sexual functioning	0–100	226	29.9 ± 28.92	377	17.8 ± 25.06
Sexual enjoyment*	0–100	110	77.6 ± 25.98	99	63.3 ± 24.51
EORTC QLQ-BR23^b
Systemic therapy side effects	0–100	236	41.7 ± 21.47	437	39.9 ± 21.34
Breast symptoms	0–100	235	24.0 ± 22.86	434	22.1 ± 20.84
Arm symptoms	0–100	235	22.3 ± 22.44	435	21.5 ± 22.19
Upset by hair loss	0–100	225	39.3 ± 40.51	423	44.6 ± 43.38
Brief fatigue inventory^b
BFI total score	0–10	225	3.2 ± 2.32	416	3.0 ± 2.31
Fatigue intensity	0–10	224	4.2 ± 2.37	402	3.6 ± 2.37
Fatigue interference	0––10	225	2.8 ± 2.52	417	2.7 ± 2.41
HADS^b
HADS total score	0–42	229	11.2 ± 6.69	419	11.5 ± 6.95
Anxiety	0–21	232	5.8 ± 3.34	424	5.9 ± 3.57
Depression	0–21	231	5.3 ± 3.97	423	5.6 ± 3.93

FACT-G global score: PWB + SWB + EWB + FWB

BFI Brief Fatigue Inventory, HADS hospital anxiety and depression scale, SD standard deviation

*If sexually active

^aHigh scores indicate high quality of life/low symptom severity

^bHigh scores indicate high symptom severity